Kacie D Deters1,2,3, Shannon L Risacher1,2, Sungeun Kim1,2,4, Kwangsik Nho1,2, John D West1, Kaj Blennow5, Henrik Zetterberg5,6, Leslie M Shaw7, John Q Trojanowski7, Michael W Weiner8, Andrew J Saykin1,2,3. 1. Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN, USA. 2. Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA. 3. Program in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN, USA. 4. Department of Electrical and Computer Engineering, State University of New York, Oswego, NY, USA. 5. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 6. Department of Molecular Neuroscience, University College London Institute of Neurology, London, UK. 7. Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 8. Department of Radiology, Medicine, and Psychiatry, University of California San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND: Peripheral (plasma) and central (cerebrospinal fluid, CSF) measures of tau are higher in Alzheimer's disease (AD) relative to prodromal stages and controls. While elevated CSF tau concentrations have been shown to be associated with lower grey matter density (GMD) in AD-specific regions, this correlation has yet to be examined for plasma in a large study. OBJECTIVE: Determine the neuroanatomical correlates of plasma tau using voxel-based analysis. METHODS: Cross-sectional data for 508 ADNI participants were collected for clinical, plasma total-tau (t-tau), CSF amyloid (Aβ42) and tau, and MRI variables. The relationship between plasma tau and GMD and between CSF t-tau and GMD were assessed on a voxel-by-voxel basis using regression models. Age, sex, APOEɛ4 status, diagnosis, and total intracranial volume were used as covariates where appropriate. Participants were defined as amyloid positive (Aβ+) if CSF Aβ42 was <192 pg/mL. RESULTS: Plasma tau was negatively correlated with GMD in the medial temporal lobe (MTL), precuneus, thalamus, and striatum. The associations with thalamus and striatum were independent of diagnosis. A negative correlation also existed between plasma tau and GMD in Aβ+ participants in the MTL, precuneus, and frontal lobe. When compared to CSF t-tau, plasma tau showed a notably different associated brain atrophy pattern, with only small overlapping regions in the fusiform gyrus. CONCLUSION: Plasma tau may serve as a non-specific marker for neurodegeneration but is still relevant to AD considering low GMD was associated with plasma tau in Aβ+ participants and not Aβ-participants.
BACKGROUND: Peripheral (plasma) and central (cerebrospinal fluid, CSF) measures of tau are higher in Alzheimer's disease (AD) relative to prodromal stages and controls. While elevated CSFtau concentrations have been shown to be associated with lower grey matter density (GMD) in AD-specific regions, this correlation has yet to be examined for plasma in a large study. OBJECTIVE: Determine the neuroanatomical correlates of plasma tau using voxel-based analysis. METHODS: Cross-sectional data for 508 ADNI participants were collected for clinical, plasma total-tau (t-tau), CSF amyloid (Aβ42) and tau, and MRI variables. The relationship between plasma tau and GMD and between CSF t-tau and GMD were assessed on a voxel-by-voxel basis using regression models. Age, sex, APOEɛ4 status, diagnosis, and total intracranial volume were used as covariates where appropriate. Participants were defined as amyloid positive (Aβ+) if CSF Aβ42 was <192 pg/mL. RESULTS: Plasma tau was negatively correlated with GMD in the medial temporal lobe (MTL), precuneus, thalamus, and striatum. The associations with thalamus and striatum were independent of diagnosis. A negative correlation also existed between plasma tau and GMD in Aβ+ participants in the MTL, precuneus, and frontal lobe. When compared to CSF t-tau, plasma tau showed a notably different associated brain atrophy pattern, with only small overlapping regions in the fusiform gyrus. CONCLUSION: Plasma tau may serve as a non-specific marker for neurodegeneration but is still relevant to AD considering low GMD was associated with plasma tau in Aβ+ participants and not Aβ-participants.
Entities:
Keywords:
Alzheimer disease; magnetic resonance imaging; mild cognitive impairment; plasma; tau protein
Authors: Jeffrey Randall; Erik Mörtberg; Gail K Provuncher; David R Fournier; David C Duffy; Sten Rubertsson; Kaj Blennow; Henrik Zetterberg; David H Wilson Journal: Resuscitation Date: 2012-08-09 Impact factor: 5.262
Authors: Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2012-05 Impact factor: 3.685
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: Bob Olsson; Ronald Lautner; Ulf Andreasson; Annika Öhrfelt; Erik Portelius; Maria Bjerke; Mikko Hölttä; Christoffer Rosén; Caroline Olsson; Gabrielle Strobel; Elizabeth Wu; Kelly Dakin; Max Petzold; Kaj Blennow; Henrik Zetterberg Journal: Lancet Neurol Date: 2016-04-08 Impact factor: 44.182
Authors: Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici Journal: Acta Neuropathol Date: 2006-08-12 Impact factor: 17.088
Authors: Matthew R Brier; Brian Gordon; Karl Friedrichsen; John McCarthy; Ari Stern; Jon Christensen; Christopher Owen; Patricia Aldea; Yi Su; Jason Hassenstab; Nigel J Cairns; David M Holtzman; Anne M Fagan; John C Morris; Tammie L S Benzinger; Beau M Ances Journal: Sci Transl Med Date: 2016-05-11 Impact factor: 17.956
Authors: Shannon L Risacher; Sungeun Kim; Li Shen; Kwangsik Nho; Tatiana Foroud; Robert C Green; Ronald C Petersen; Clifford R Jack; Paul S Aisen; Robert A Koeppe; William J Jagust; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Andrew J Saykin Journal: Front Aging Neurosci Date: 2013-04-01 Impact factor: 5.750
Authors: Henrik Zetterberg; David Wilson; Ulf Andreasson; Lennart Minthon; Kaj Blennow; Jeffrey Randall; Oskar Hansson Journal: Alzheimers Res Ther Date: 2013-03-28 Impact factor: 6.982
Authors: Niklas Mattsson; Henrik Zetterberg; Shorena Janelidze; Philip S Insel; Ulf Andreasson; Erik Stomrud; Sebastian Palmqvist; David Baker; Cristina A Tan Hehir; Andreas Jeromin; David Hanlon; Linan Song; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Oskar Hansson; Kaj Blennow Journal: Neurology Date: 2016-09-30 Impact factor: 9.910
Authors: Zhicheng Chen; David Mengel; Ashvini Keshavan; Robert A Rissman; Andrew Billinton; Michael Perkinton; Jennifer Percival-Alwyn; Aaron Schultz; Michael Properzi; Keith Johnson; Dennis J Selkoe; Reisa A Sperling; Purvish Patel; Henrik Zetterberg; Douglas Galasko; Jonathan M Schott; Dominic M Walsh Journal: Alzheimers Dement Date: 2018-11-09 Impact factor: 21.566
Authors: Thomas K Karikari; Nicholas J Ashton; Gunnar Brinkmalm; Wagner S Brum; Andréa L Benedet; Laia Montoliu-Gaya; Juan Lantero-Rodriguez; Tharick Ali Pascoal; Marc Suárez-Calvet; Pedro Rosa-Neto; Kaj Blennow; Henrik Zetterberg Journal: Nat Rev Neurol Date: 2022-05-18 Impact factor: 44.711
Authors: Shannon M Drouin; G Peggy McFall; Olivier Potvin; Pierre Bellec; Mario Masellis; Simon Duchesne; Roger A Dixon Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Michael L Alosco; Yorghos Tripodis; Nathan G Fritts; Amanda Heslegrave; Christine M Baugh; Shannon Conneely; Megan Mariani; Brett M Martin; Samuel Frank; Jesse Mez; Thor D Stein; Robert C Cantu; Ann C McKee; Leslie M Shaw; John Q Trojanowski; Kaj Blennow; Henrik Zetterberg; Robert A Stern Journal: Alzheimers Dement Date: 2018-07-23 Impact factor: 21.566
Authors: Inge M W Verberk; Rosalinde E Slot; Sander C J Verfaillie; Hans Heijst; Niels D Prins; Bart N M van Berckel; Philip Scheltens; Charlotte E Teunissen; Wiesje M van der Flier Journal: Ann Neurol Date: 2018-10-04 Impact factor: 10.422
Authors: Harald Hampel; Andrea Vergallo; Mohammad Afshar; Leyla Akman-Anderson; Joaquín Arenas; Norbert Benda; Richard Batrla; Karl Broich; Filippo Caraci; A Claudio Cuello; Enzo Emanuele; Marion Haberkamp; Steven J Kiddle; Alejandro Lucía; Mark Mapstone; Steven R Verdooner; Janet Woodcock; Simone Lista Journal: Dialogues Clin Neurosci Date: 2019 Impact factor: 5.986
Authors: José Luis Molinuevo; Scott Ayton; Richard Batrla; Martin M Bednar; Tobias Bittner; Jeffrey Cummings; Anne M Fagan; Harald Hampel; Michelle M Mielke; Alvydas Mikulskis; Sid O'Bryant; Philip Scheltens; Jeffrey Sevigny; Leslie M Shaw; Holly D Soares; Gary Tong; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow Journal: Acta Neuropathol Date: 2018-11-28 Impact factor: 17.088